Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003264 · ClinicalTrials.gov registry record · Phase 2
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 12
- Study locations
NCT00003264: Completed Phase 2 study of Head and Neck Cancer, sponsored by Fox Chase Cancer Center.
NCT00003264 is a Phase 2 study of Head and Neck Cancer that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 22 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003264, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 12
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with advanced squamous cell head and neck cancer that cannot be treated by surgery or radiation therapy.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
Study Locations (12)
Pennsylvania
- St. Luke's Network - Bethlehem - Bethlehem
- Delaware County Memorial Hospital - Drexel Hill
- Harrisburg Polyclinic Medical Center - Harrisburg
- Saint Mary Regional Center - Langhorne
- North Penn Hospital - Lansdale
- Paoli Memorial Hospital - Paoli
- Fox Chase Cancer Center - Philadelphia
- Reading Hospital and Medical Center - Reading
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
- Riverview Medical Center - Booker Cancer Center - Red Bank
- St. Francis Medical Center - Trenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 1997-10 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
What the finished NCT00003264 record still lists
NCT00003264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.
NCT00003264 lists 12 locations in 2 states (Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00003264 about?
NCT00003264 is a clinical study titled "Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with advanced squamou...
What is the current status of trial NCT00003264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 1997-10. Estimated completion is 2002-06.
What conditions does trial NCT00003264 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00003264?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003264?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003264 being conducted?
This trial has 12 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003264's enrollment target sits among peer trials
22 214th of 250 higher than 33 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia